Alzheimer’s Drug Coverage Plan Spurs Call for Becerra to Step In (1)

An Alzheimer’s patient advocacy group is urging the Biden administration to allow broader coverage of Biogen’s Aduhelm, the latest call for action in an ongoing debate over who should be able to access the controversial drug.

FDA approval of a drug usually leads to Medicare coverage. But the extraordinary circumstances surrounding Aduhelm’s path through the agency, along with the sheer scope and costs related to the drug, prompted the administration to propose limiting coverage to patients enrolled in clinical trials. Advocacy groups say that threatens access to minorities and other groups that are typically underrepresented in drug studies.

“This is ...